Asayama Yoshiki, Nishie Akihiro, Ishigami Kousei, Ushijima Yasuhiro, Takayama Yukihisa, Okamoto Daisuke, Fujita Nobuhiro, Morita Koichiro, Honda Hiroshi
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.
Department of Radiology Informatics and Network, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.
Springerplus. 2016 Feb 24;5:157. doi: 10.1186/s40064-016-1880-7. eCollection 2016.
To clarify the hemodynamic changes under balloon occlusion of the hepatic artery and to identify predictors of the short-term therapeutic effect (TE) after balloon-occluded transcatheter arterial chemoembolization using miriplatin (B-TACE) for hepatocellular carcinoma (HCC). Tumor variables and angiographic data were collected for 35 nodules (29 patients) with a B-TACE for HCC. Lesions were classified into three groups based on the balloon-occluded CT hepatic arteriography (BO-CTHA) results: Group A, presence of corona enhancement; Group B, absence of corona enhancement; Group C, decreased perfusion or perfusion defect compared to standard CTHA. Objective response was defined as TE3/4, and poor TE as TE1/2, evaluated by response evaluation criteria in cancer of the liver at 1-4 months after the procedure. Univariate analysis revealed that proximal level of balloon occlusion, intratumoral lower CT values immediately after treatment and BO-CTHA findings were significantly correlated with poor TE (p = 0.034, 0.037, and 0.003, respectively). Multivariate logistic analysis identified the Group C as a significant factor associated with the worse short term TE (odds ratio 8.34; 95 % confidence interval 1.49-68.8). Partial or complete perfusion defect on BO-CTHA was an independent factor associated with poor therapeutic effect.
为明确肝动脉球囊阻断下的血流动力学变化,并确定使用米铂进行球囊阻断经导管动脉化疗栓塞术(B-TACE)治疗肝细胞癌(HCC)后短期治疗效果(TE)的预测因素。收集了35个接受HCC的B-TACE治疗的结节(29例患者)的肿瘤变量和血管造影数据。根据球囊阻断CT肝动脉造影(BO-CTHA)结果将病变分为三组:A组,存在冠状强化;B组,无冠状强化;C组,与标准CTHA相比灌注降低或灌注缺损。根据肝脏肿瘤疗效评价标准在术后1-4个月评估客观缓解为TE3/4,不良TE为TE1/2。单因素分析显示,球囊阻断近端水平、治疗后即刻肿瘤内较低CT值和BO-CTHA表现与不良TE显著相关(分别为p = 0.034、0.037和0.003)。多因素逻辑分析确定C组是与短期TE较差相关的显著因素(比值比8.34;95%置信区间1.49-68.8)。BO-CTHA上的部分或完全灌注缺损是与治疗效果不佳相关的独立因素。